Shilpa Medicare Q2 profit slips to 45.37 cr
Shilpa Medicare Limited has posted 10.63 per cent lower profits at 45.37 crore on a consolidated basis for the second quarter (Q2) of FY21 as agains02-11-2020
02-11-2020
SHILPA MEDICARE LTD. - 530549 - Outcome Of Board Meeting Held On 02Nd November 2020.
With reference to the captioned subject, Please be noted that pursuant to the Resolution passed at the meeting of the board of directors held on 02nd November, 2020 at 11:00 A.M. the following items have taken on record. 1. The unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2020 pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015.02-11-2020
SHILPA MEDICARE LTD. - 530549 - Outcome Of Board Meeting
With reference to the captioned subject, Please be noted that pursuant to the Resolution passed at the meeting of the board of directors held on 02nd November, 2020 at 11:00 A.M. the following items have taken on record. 1. The unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2020 pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015. The meeting commenced at 11:00 A.M. and concluded at 01:15 P.M02-11-2020
SHILPA MEDICARE LTD. - 530549 - Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2020 ,inter alia, to consider and approve With reference to the subject cited above, we wish to inform you that a meeting of the Board of Directors of Shilpa Medicare Limited will be held on Monday, the 02nd Day of November, 2020 to inter alia transact the following items of business: Approval of the Un Audited Standalone and Consolidated Financial Results of the Company for Second Quarter ended 30th September, 2020.27-10-2020
SHILPA MEDICARE LTD. - 530549 - Compliance Certificate For Half Year Ended 30Th September, 2020
With reference to the subject cited above, please find attached herewith the Compliance Certificate under Regulation 40(9) of SEBI (LODR) Regulations, 2015, issued by the Practicing Company Secretary M/s P.S Rao & Associates.19-10-2020
SHILPA MEDICARE LTD. - 530549 - Shareholding for the Period Ended September 30, 2020
Shilpa Medicare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2020. For more details, kindly Click here13-10-2020
SHILPA MEDICARE LTD. - 530549 - Statement Of Investor Complaints For The Quarter Ended September 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- V V KRISHNA CHAITANYADesignation :- Company Secretary and Compliance Officer13-10-2020
Shilpa Medicare slips 12% on USFDA warning letter for Telangana facility
The company believes that the warning letter will have minimum impact of disruption of supplies and the existing revenues from operations of this facility12-10-2020
SHILPA MEDICARE LTD. - 530549 - Disclosure Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015
Dear Sir, This is to inform that the Company, has received a warning letter yesterday i.e on 9th October 2020 at 10:06 PM (India Time) through email from the USFDA for its Jadcherla facility, Telangana. We will be engaging with the agency and are fully committed in resolving this issue at the earliest. The Company is also committed in maintaining the highest standards of compliances and quality manufacturing across all its facilities. The Company believes that the warning letter will have minimum impact of disruption of supplies and the existing revenues from operations of this facility. Shilpa Medicare Ltd currently has three manufacturing facilities approved by USFDA - One formulation facility and two API facilities. None of these facilities except Jadcherla has any outstanding issues with the USFDA at this point of time. This is for your information and records please.10-10-2020
SHILPA MEDICARE LTD. - 530549 - Compliance Certificate For Half Year Ended 30.09.2020
With reference to the subject cited above, please find attached herewith the Compliance Certificate under Regulation 7(3) of SEBI (LODR) Regulations, 2015, issued by the Company and the RTA i.e. M/s. KFin Technologies Private Limited.08-10-2020